Summary
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%–80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy, followed by administration of PSK and carboquone (CQ) in small amounts as maintenance therapy continuously for about 3 years, and the course was observed.
In both consolidation and maintenance groups various non-specific immunoparameters were superior in groups receiving combined immunotherapeutic agents. Thus, the use of immunotherapeutic agents in combination with chemotherapeutic agents was considered to be effective. The 3-year recurrence rate was only 8% in the multidisciplinary treatment group, while that in the non-multidisciplinary treatment group was 61%. This approach, especially with chemoimmunotherapy (ADM and OK-432) as a consolidation therapeutic mode, is therefore considered to be useful for the prevention of recurrence.
Similar content being viewed by others
References
Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729–747
Cohen J (1969) Statistical power analysis for the behavioral sciences. Academic Press, New York
Dekernion JB, Skinner DG (1978) Epidemiology, diagnosis, and staging of bladder cancer. In: Skinner DG (ed) Genitourinary cancer. Saunders, Philadelphia London Toronto, pp 213–231
Gehan EA, Freireich EJ (1974) Non-randomized controls in cancer clinical trials. N Engl J Med 290: 198–203
Hoshino T, Uchida A, et al (1976) Immunotherapy of cancer with immunostimulants. Jpn J Clin Immunol 8: 1105–1114
Karnofsky DA (1961) Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 2: 709–712
Mathé G, et al (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet I: 697
Morton DL, et al (1974) BCG immunotherapy of malignant melanoma. Summary of seven year's experience. Ann Surg 180: 635
Nakagami Y, et al (1978a) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. J Nippon Med Sch 45: 284–286
Nakagami Y, et al (1978b) Adjuvant immunotherapy with antitumor Str. pyogenes preparation in urogenital carcinoma. (Abstract) XIIth International Congress of Cancer in Buenos Aires, Workshop #28 No. 2, 71
Nakagami Y, et al (1979) Adjuvant immunotherapy with antitumor Str. pyogenes preparation (immunopotentiator OK-432) in urogenital carcinoma. Acta Urol Jap 25: 133–141
Niijima T (1978) Intravesical therapy with adriamycin and new trends in the diagnostics and therapy of superficial urinary bladder tumours. WHO center meeting records, pp 37–44
Persky L, Krush ED, Soloway M (1978) Urotherlial tumors. In: Devine CJ Jr (ed) Urology in practice. Little, Brown, Boston, pp 653–690
Turner AG, Durrant KR, Malpas JS (1979) A trial of bleomycin versus adriamycin in advanced carcinoma of the bladder. Br J Urol 51: 121–124
Union Internationale Contre le Cancer (1978) TNM classification of malignant tumors. UICC, Geneve, pp 113–117
Wallace DM, Bloom HJG (1976) The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (First report). Br J Urol 48: 587–594
Weinstein SH, Schmidt JD (1976) Doxorubicin chemotherapy in advanced transitional cell carcinoma. Urology 8: 336–341
Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, Krakoff IH (1977) Adriamycin in advanced urinary tract cancer. Cancer 39: 279–285
Yata J (1978) Cells involved in immune responses and their rules. Jpn J Dermatol [B] 88: 607–613
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakagami, Y., Minowa, T., Tozuka, K. et al. Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy. Cancer Chemother. Pharmacol. 11 (Suppl 1), S47–S50 (1983). https://doi.org/10.1007/BF00256718
Issue Date:
DOI: https://doi.org/10.1007/BF00256718